Comparison Between Perioperative and Postoperative Chemotherapy After Potentially Curative Hepatic Resection for Metastatic Colorectal Cancer

Araujo, Raphael; Gonen, Mithat; Allen, Peter; Blumgart, Leslie; DeMatteo, Ronald; Fong, Yuman; Kemeny, Nancy; Jarnagin, William; D’Angelica, Michael
December 2013
Annals of Surgical Oncology: An Oncology Journal for Surgeons;Dec2013, Vol. 20 Issue 13, p4312
Academic Journal
No abstract available.


Related Articles

  • The feasibility and potential benefit of preoperative chemotherapy for colorectal liver metastasis (CLM): a single-centered retrospective study. Kataoka, Kozo; Kanazawa, Akiyoshi; Nakajima, Akio; Yamaguchi, Ayane; Arimoto, Akira; Kohno, Yukihiro // Surgery Today;Oct2013, Vol. 43 Issue 10, p1154 

    Purposes: The benefit of neo-adjuvant chemotherapy for liver-limited metastatic colorectal cancer is still controversial. This study defined the resectability regardless of the size and number of liver metastases, and attempted curative hepatic resection in all cases. Methods: Sixty-four...

  • Perioperative treatments for resectable gastric cancer. Sook Ryun Park; Yoon-Koo Kang // Journal of the Korean Medical Association / Taehan Uisa Hyophoe ;Mar2015, Vol. 58 Issue 3, p201 

    Although surgical resection remains the only curative treatment for gastric cancer, locoregional and distant recurrence are still common after surgical resection with curative intent underscoring the importance of a multimodal approach. In recent decades, there have been notable improvements in...

  • Trends in the Multimodality Treatment of Resectable Colorectal Liver Metastases: an Underutilized Strategy. Parikh, Alexander; Ni, Shenghua; Koyama, Tatsuki; Pawlik, Timothy; Penson, David // Journal of Gastrointestinal Surgery;Nov2013, Vol. 17 Issue 11, p1938 

    Objective: Advances in multimodality therapy have led to increased survival for patients with metastatic colorectal cancer, but the impact on patients undergoing resection for colorectal liver metastases is unclear. The purpose of this study was to evaluate patterns of treatment for resectable...

  • Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01). Mitsukuni Suenaga; Yoshiya Fujimoto; Satoshi Matsusaka; Eiji Shinozaki; Takashi Akiyoshi; Satoshi Nagayama; Yosuke Fukunaga; Masatoshi Oya; Masashi Ueno; Nobuyuki Mizunuma; Toshiharu Yamaguchi // OncoTargets & Therapy;2015, Vol. 8, p1111 

    Background: Perioperative chemotherapy combined with surgery for liver metastases is considered an active strategy in metastatic colorectal cancer (CRC). However, its impact on initially unresectable, previously untreated advanced CRC, regardless of concurrent metastases, remains to be...

  • Survival after Hepatectomy for Metastatic Colorectal Cancer in the Presence of Resectable Extrahepatic Disease. Chokshi, Ravi J.; Ioannis Hatzaras; Neff, Ryan; Schmidt, Carl; Brady, Colin; Malhotra, Lavina; Martin, Edward; Bloomston, Mark // Ibnosina Journal of Medicine & Biomedical Sciences;2014, Vol. 6 Issue 2, p67 

    Background: The presence of extrahepatic disease, bilobar disease or greater than four hepatic lesions were once considered contraindications to hepatectomy for colorectal metastases but are being reconsidered. We reviewed our experience with resection of extrahepatic disease (EHD) at the time...

  • Liver resection for colorectal cancer metastases. Gallinger, S.; Biagi, J. J.; Fletcher, G. G.; Nhan, C.; Ruo, L.; McLeod, R. S. // Current Oncology;Jun2013, Vol. 20 Issue 3, pe255 

    Questions 1. Should surgery be considered for colorectal cancer (CRC) patients who have liver metastases plus (a) pulmonary metastases, (b) portal nodal disease, or (c) other extrahepatic metastases (EHMs)? 2. What is the role of chemotherapy in the surgical management of CRC with liver...

  • Surgical Therapy for Colorectal Metastases to the Liver. Pawlik, Timothy M.; Choti, Michael A. // Journal of Gastrointestinal Surgery;Aug2007, Vol. 11 Issue 8, p1057 

    Colorectal cancer is the fourth most common type of cancer in the West and the second leading cause of cancer-related deaths in the United States. Approximately 35 to 55% of patients with colorectal cancer develop hepatic metastases during the course of their disease. Surgical resection of...

  • Hepatic Toxicities Associated with the Use of Preoperative Systemic Therapy in Patients with Metastatic Colorectal Adenocarcinoma to the Liver. CLEARY, JAMES M.; TANABE, KENNETH T.; LAUWERS, GREGORY Y.; ZHU, ANDREW X. // Oncologist;Nov2009, Vol. 14 Issue 11, p1095 

    Colorectal cancer patients with isolated liver metastasis are potentially cured with surgical resection. Recent advances in systemic chemotherapy have increased the ability to convert unresectable metastatic liver lesions to resectable lesions. The cost in toxicity of these therapeutic advances...

  • T Cells and Adoptive Immunotherapy: Recent Developments and Future Prospects in Gastrointestinal Oncology. Amedei, Amedeo; Niccolai, Elena; D'Elios, Mario M. // Clinical & Developmental Immunology;2011, p1 

    Gastrointestinal oncology is one of the foremost causes of death: the gastric cancer accounts for 10.4% of cancer deaths worldwide, the pancreatic cancer for 6%, and finally, the colorectal cancer for 9% of all cancer-related deaths. For all these gastrointestinal cancers, surgical tumor...

  • Adverse Reaction Research.  // Reactions Weekly;11/15/2008, Issue 1228, p3 

    The article discusses research being done on preoperative bevacizumab. It references a study by S. B. Kesmodel et al published in the November 10, 2008 issue of the "Journal of Clinical Oncology." The study concluded that the addition of bevacizumab to preoperative chemotherapy is not associated...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics